Overactive bladder (OAB) is associated with systemic chronic inflammation. Indices derived from complete blood count (such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)) have shown associations with OAB presence. However, whether baseline inflammatory status predicts response to beta-3 adrenergic agonist therapy remains untested. This prospective observational cohort study evaluates the predictive ability of baseline NLR, PLR, and SII for 3-month treatment response to mirabegron 50 mg in women with OAB.
Female patients aged 18 years or older
Overactive bladder symptoms for at least 3 months
Mirabegron 50 mg planned by physician decision within routine care
Ability to provide written informed consent
Any previous OAB-specific treatment other than behavioral therapy (oral antimuscarinic or beta-3 agonist, intravesical botulinum toxin, sacral neuromodulation, or posterior tibial nerve stimulation)
Acute infection within the last 4 weeks, including culture-confirmed urinary tract infection
Chronic inflammatory disease (rheumatologic or autoimmune disease, or inflammatory bowel disease)
Active malignancy or cancer treatment within the last 5 years